Abstract
British Journal of DermatologyVolume 186, Issue 6 p. e263-e263 Plain Language Summary How can interleukin-I antagonists be developed to treat skin diseases? First published: 03 June 2022 https://doi.org/10.1111/bjd.21304AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Linked Article: Calabrese et al. Br J Dermatol 2022; 186:925–941. The interleukin-1 (IL-1) family are a group of chemicals called cytokines that form part of our immune system. Unfortunately, the body may start to use these cytokines inappropriately (dysregulation), and they may stimulate certain white blood cells (neutrophils) to increase in number causing inflammation without an infectious trigger. In this paper, the authors from Italy and Germany review the role of the different members of the IL-1 family in inflammatory skin disorders and the progress being made to develop antibody treatments aiming to reverse their effects. Interleukin-1 antagonists such as anakinra and canakinumab have already proved useful in the treatment of disorders directly related to neutrophil proliferation, but there is evidence that this group of drugs may also be beneficial in commoner disorders such as psoriasis and atopic eczema. Sometimes a drug that blocks a single cytokine molecule may have limited effect. Laboratory studies suggest that agents that block receptors on the cell surface membrane may be more effective at reducing skin inflammation caused by several IL-1 subsets. One promising target is IL-1 receptor accessory protein (IL-1R3). The authors stress the need for drugs that target the harmful effects of the IL-1 family at several levels. Volume186, Issue6June 2022Pages e263-e263 RelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
